基于前哨淋巴结识别的cN0头颈癌个体化预防性颈部照射:前瞻性1-2期研究最终结果
基于淋巴显像的临床靶体积较国际指南缩小2倍,中位随访46个月仅1例在未照射区域出现区域复发,危及器官剂量和正常组织并发症概率降低,6个月生活质量改善。
要点
- SPECT/CT前哨淋巴结定位可使预防性颈部靶体积较指南缩小2倍。
- 中位随访46个月仅1例在未照射区域出现区域复发。
- 对侧唾液腺和甲状腺剂量显著降低,口干、吞咽困难、甲状腺功能减退NTCP下降。
核心结论
- SPECT/CT颈部前哨淋巴结定位可个体化并缩小预防性颈部靶体积,而不影响区域控制。
- 正常组织并发症概率降低,所有患者尤其单侧照射者观察到良好生活质量。
研究设计与样本
- 肿瘤周围注射99mTc纳米胶体后行SPECT/CT显像,选择含最多4枚最热前哨淋巴结的颈部区域进行预防照射。
- 基于现行国际指南选择颈部区域进行对比虚拟计划,比较危及器官剂量学数据。
主要发现
- 基于淋巴显像的淋巴结临床靶体积较基于国际指南者小2倍(P < .0001)。
- 中位随访46个月,仅1例患者在未照射区域出现区域复发。
- 单侧引流患者对侧唾液腺中位剂量降低14.6-28.1 Gy,所有患者甲状腺中位剂量降低22.4-48.9 Gy。
- 口干、吞咽困难、甲状腺功能减退的中位NTCP分别降低0.3%-13.7%、1.7%-10.8%、14.0%-36.1%,6个月生活质量改善尤其见于单侧照射患者。
关键数值与推荐
- 选择含最多4枚最热前哨淋巴结的颈部区域进行预防照射。
- 基于淋巴显像的淋巴结临床靶体积较国际指南缩小2倍(P < .0001)。
- 单侧引流患者对侧唾液腺中位剂量降低14.6-28.1 Gy。
- 所有患者甲状腺中位剂量降低22.4-48.9 Gy。
- 口干NTCP中位降低0.3%-13.7%,吞咽困难降低1.7%-10.8%,甲状腺功能减退降低14.0%-36.1%。
临床怎么用
- 对临床N0头颈鳞癌根治性放疗患者,可考虑SPECT/CT前哨淋巴结定位个体化预防照射颈部区域。
- 该策略可缩小预防性颈部靶体积并降低危及器官剂量,尤其利于单侧引流患者。
- 应用时需注意部分患者存在未预测淋巴引流,48%为单侧引流。
局限性
- 随访中位46个月,区域复发事件仅1例。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: This prospective, nonrandomized, interventional phase 1-2 study investigated the individualization of elective node irradiation in clinically N0 head and neck squamous cell carcinoma by sentinel lymph node (SLN) mapping with single-photon emission computed tomography/computed tomography (SPECT/CT) and its impact on tumor control and radiation-related toxicity. METHODS AND MATERIALS: Forty-four patients with clinically N0 head and neck squamous cell carcinoma treated with definitive (chemo-)radiation therapy were imaged with SPECT/CT after 99mTc nanocolloid injection around the tumor. The neck levels containing up to the 4 hottest SLNs were selected for prophylactic irradiation. A comparative virtual planning was performed with the selection of neck levels based on the current international guidelines. Regional control was monitored as a function of the selected volume. Dosimetric data for the organs at risk were compared between the plans. Normal tissue complication probability (NTCP) rates were derived for xerostomia, dysphagia, and hypothyroidism to predict the clinical benefit and correlated to quality-of-life (QoL) assessments at 6 months. RESULTS: Sixteen percent of patients presented unpredicted lymphatic drainage, and 48% drained unilaterally. The nodal clinical target volume based on lymphoscintigraphy was smaller than the nodal clinical target volume based on international guidelines by a factor of 2 (P < .0001). After a median follow-up of 46 months, only 1 patient experienced a regional relapse in a nonirradiated area. Significant median dose reductions to organs at risk were observed, particularly to contralateral salivary glands in patients with unilateral drainage (14.6-28.1 Gy) and to the thyroid gland in all patients (22.4-48.9 Gy). Median NTCP reductions were observed for xerostomia (0.3% to 13.7%), dysphagia (1.7% to 10.8%), and hypothyroidism (14.0% to 36.1%). QoL at 6 months was improved, particularly in patients irradiated unilaterally. CONCLUSIONS: Neck SLN mapping with SPECT/CT individualizes and reduces the elective nodal target volumes without compromising the regional control. The NTCP rates were reduced and favorable QoL were observed in all patients, particularly in the case of unilateral irradiation.
引用
- Longton E, Lawson G, Bihin B, et al. Individualized Prophylactic Neck Irradiation in Patients with cN0 Head and Neck Cancer Based on Sentinel Lymph Node(s) Identification: Definitive Results of a Prospective Phase 1-2 Study. Int J Radiat Oncol Biol Phys. 2020. PMID: 32294522. doi:10.1016/j.ijrobp.2020.03.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。